Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces it has entered into a co-development collaboration agreement with Ergomed plc (LON:ERGO) for the
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, has today announced that Manuel Llobet, Chief Executive Officer, will be presenting at the Jefferies 2017
Allergy Therapeutics plc (LON:AGY) yesterday published the following documents: · Annual Report for the year ended 30 June 2017 (“Annual Report”); and · Notice of 2017 Annual General Meeting (“Notice of Meeting”);
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announced that dosing has commenced in its G205 Phase II study designed to evaluate the
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in the EU only
Allergy Therapeutics plc (LON:AGY) Finance Director Nick Wykeman and Chief Executive Officer Manuel Llobet spoke to Proactive Investors about another year of strong growth for the company.
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announced its preliminary results for the year ended 30 June 2017. Financial highlights · 72% increase
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces that the fully-funded Phase II clinical trial investigating the dosing of PQ Grass has
Murray Skinner, Chief Scientific Officer of Allergy Therapeutics, commented: “We are delighted to welcome Pieter-Jan and Simon to the Allergy Therapeutics team. Their vast experience and expert knowledge is ideally
Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, will issue its preliminary results for the year ended 30 June 2017 on Thursday 28 September 2017.
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
